ATTO
Attovia Therapeutics, Inc.
Price Chart
Latest Quote
$14.18
+0.30 (+2.16%)
Current Price
| Previous Close | $13.88 |
| Open | $14.19 |
| Day High | $14.33 |
| Day Low | $13.63 |
| Volume | 164,522 |
Stock Information
| Shares Outstanding | 45.65M |
| Total Debt | $4.33M |
| Cash Equivalents | $115.13M |
| Revenue | $1.80M |
| Net Income | $-70.11M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $647.33M |
| EPS (TTM) | $-2.74 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $781.06M |
| Sales | $1.80M |
| Income | $-70.11M |
| Book/sh | $-32.12 |
| Cash/sh | $2.52 |
| Employees | 44 |
Financial Ratios
| Quick Ratio | 9.20 |
| Current Ratio | 9.39 |
| Debt/Eq | 3.84 |
Returns & Margins
| Operating Margin | -4845.11% |
Ownership
| Insider Ownership | 9.05% |
| Institutional Ownership | 37.95% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.96 |
| P/S | 359.63 |
| P/B | -0.44 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $42.20 |
Technical Indicators
| SMA20 | $15.39 |
| SMA50 | $19.04 |
| RSI | 28.54 |
| ATR | 1.1864 |
| Shares Float | 26.26M |
| Short Ratio | 4.24 |
| Rel Volume | 0.40 |
Performance History
| Week | +1.00% |
| Month | -19.66% |
| YTD | -35.25% |
| 10 Years | -35.25% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $14.18 | 164,522 |
| 2026-10-26 | $13.88 | 224,600 |
| 2026-10-23 | $13.83 | 330,700 |
| 2026-10-22 | $14.50 | 189,100 |
| 2026-10-21 | $14.18 | 279,900 |
| 2026-10-20 | $14.04 | 448,400 |
| 2026-10-19 | $13.89 | 297,500 |
| 2026-10-16 | $13.73 | 977,900 |
| 2026-10-15 | $14.78 | 641,400 |
| 2026-10-14 | $14.96 | 359,600 |
| 2026-10-13 | $14.72 | 399,500 |
| 2026-10-12 | $14.59 | 262,300 |
| 2026-10-09 | $16.21 | 194,200 |
| 2026-10-08 | $16.31 | 418,100 |
| 2026-10-07 | $16.42 | 515,700 |
| 2026-10-06 | $17.50 | 521,700 |
| 2026-10-05 | $18.00 | 456,000 |
| 2026-10-02 | $17.17 | 348,700 |
| 2026-10-01 | $17.79 | 530,800 |
| 2026-09-30 | $17.14 | 769,600 |
| 2026-09-29 | $18.16 | 887,300 |
| 2026-09-28 | $17.65 | 403,000 |
About Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4Ã7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on ATTO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $1,350,000 | $0 |
| Operating Revenue | $1,350,000 | $0 |
| Expenses | ||
| Total Expenses | $68,509,000 | $41,553,000 |
| Other Income Expense | $-95,000 | $-1,685,000 |
| Other Non Operating Income Expenses | $-95,000 | $-1,685,000 |
| Net Non Operating Interest Income Expense | $6,627,000 | $3,437,000 |
| Operating Expense | $68,509,000 | $41,553,000 |
| General And Administrative Expense | $14,356,000 | $7,689,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-60,627,000 | $-39,801,000 |
| Net Interest Income | $6,627,000 | $3,437,000 |
| Interest Income | $6,627,000 | $3,437,000 |
| Normalized Income | $-60,627,000 | $-39,801,000 |
| Net Income From Continuing And Discontinued Operation | $-60,627,000 | $-39,801,000 |
| Total Operating Income As Reported | $-67,159,000 | $-41,553,000 |
| Net Income Common Stockholders | $-60,898,000 | $-45,046,000 |
| Net Income | $-60,627,000 | $-39,801,000 |
| Net Income Including Noncontrolling Interests | $-60,627,000 | $-39,801,000 |
| Net Income Extraordinary | $-271,000 | $-5,245,000 |
| Net Income Continuous Operations | $-60,627,000 | $-39,801,000 |
| Pretax Income | $-60,627,000 | $-39,801,000 |
| Interest Income Non Operating | $6,627,000 | $3,437,000 |
| Operating Income | $-67,159,000 | $-41,553,000 |
| Per Share | ||
| Diluted EPS | $-2.37 | $-1.75 |
| Basic EPS | $-2.37 | $-1.75 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-66,355,000 | $-41,240,000 |
| Reconciled Depreciation | $804,000 | $313,000 |
| EBITDA (Bullshit earnings) | $-66,355,000 | $-41,240,000 |
| EBIT | $-67,159,000 | $-41,553,000 |
| Diluted Average Shares | $25,467,421 | $25,671,159 |
| Basic Average Shares | $25,467,421 | $25,671,159 |
| Diluted NI Availto Com Stockholders | $-60,898,000 | $-45,046,000 |
| Otherunder Preferred Stock Dividend | $271,000 | $5,245,000 |
| Research And Development | $54,153,000 | $33,864,000 |
| Selling General And Administration | $14,356,000 | $7,689,000 |
| Other Gand A | $14,356,000 | $7,689,000 |
Fetched: 2026-10-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-107,436,000 | $-46,825,000 |
| Total Assets | $165,893,000 | $76,716,000 |
| Total Non Current Assets | $9,598,000 | $4,234,000 |
| Other Non Current Assets | $1,733,000 | $1,000,000 |
| Current Assets | $156,295,000 | $72,482,000 |
| Other Current Assets | $4,027,000 | $3,159,000 |
| Receivables | $900,000 | $125,000 |
| Accrued Interest Receivable | $900,000 | $100,000 |
| Cash Cash Equivalents And Short Term Investments | $152,268,000 | $69,323,000 |
| Cash And Cash Equivalents | $40,193,000 | $30,632,000 |
| Debt | ||
| Total Debt | $5,262,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $3,341,000 | $0 |
| Current Debt And Capital Lease Obligation | $1,921,000 | - |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $273,329,000 | $123,541,000 |
| Total Non Current Liabilities Net Minority Interest | $262,322,000 | $115,819,000 |
| Other Non Current Liabilities | $755,000 | $228,000 |
| Current Liabilities | $11,007,000 | $7,722,000 |
| Current Deferred Liabilities | $450,000 | $0 |
| Payables And Accrued Expenses | $5,533,000 | $5,658,000 |
| Payables | $3,551,000 | $4,140,000 |
| Accounts Payable | $3,551,000 | $4,140,000 |
| Equity | ||
| Common Stock Equity | $-107,436,000 | $-46,825,000 |
| Total Equity Gross Minority Interest | $-107,436,000 | $-46,825,000 |
| Stockholders Equity | $-107,436,000 | $-46,825,000 |
| Gains Losses Not Affecting Retained Earnings | $99,000 | $67,000 |
| Other Equity Adjustments | $99,000 | $67,000 |
| Retained Earnings | $-111,010,000 | $-50,383,000 |
| Preferred Securities Outside Stock Equity | $258,226,000 | $115,591,000 |
| Other | ||
| Ordinary Shares Number | $43,029,017 | $43,029,017 |
| Share Issued | $43,029,017 | $43,029,017 |
| Tangible Book Value | $-107,436,000 | $-46,825,000 |
| Invested Capital | $-107,436,000 | $-46,825,000 |
| Working Capital | $145,288,000 | $64,760,000 |
| Capital Lease Obligations | $5,262,000 | $0 |
| Total Capitalization | $-107,436,000 | $-46,825,000 |
| Additional Paid In Capital | $3,474,000 | $3,490,000 |
| Capital Stock | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $3,341,000 | $0 |
| Current Deferred Revenue | $450,000 | $0 |
| Current Capital Lease Obligation | $1,921,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,103,000 | $2,064,000 |
| Current Accrued Expenses | $1,982,000 | $1,518,000 |
| Net PPE | $7,865,000 | $3,234,000 |
| Accumulated Depreciation | $-1,097,000 | $-295,000 |
| Gross PPE | $8,962,000 | $3,529,000 |
| Leases | $136,000 | $0 |
| Construction In Progress | $28,000 | $1,570,000 |
| Other Properties | $8,280,000 | $1,820,000 |
| Machinery Furniture Equipment | $518,000 | $139,000 |
| Properties | $0 | $0 |
| Duefrom Related Parties Current | $0 | $25,000 |
| Other Short Term Investments | $112,075,000 | $38,691,000 |
Fetched: 2026-10-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-61,512,000 | $-36,807,000 |
| Operating Activities | ||
| Operating Cash Flow | $-59,199,000 | $-35,035,000 |
| Cash Flow From Continuing Operating Activities | $-59,199,000 | $-35,035,000 |
| Operating Gains Losses | $7,000 | $7,000 |
| Investing Activities | ||
| Capital Expenditure | $-2,313,000 | $-1,772,000 |
| Investing Cash Flow | $-73,455,000 | $-39,804,000 |
| Cash Flow From Continuing Investing Activities | $-73,455,000 | $-39,804,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $142,388,000 | $82,936,000 |
| Financing Cash Flow | $142,012,000 | $82,746,000 |
| Cash Flow From Continuing Financing Activities | $142,012,000 | $82,746,000 |
| Net Other Financing Charges | $-376,000 | $-19,000 |
| Net Preferred Stock Issuance | $142,194,000 | $82,626,000 |
| Preferred Stock Issuance | $142,194,000 | $82,626,000 |
| Net Common Stock Issuance | $194,000 | $310,000 |
| Common Stock Issuance | $194,000 | $310,000 |
| Other | ||
| Repayment Of Debt | $0 | $-171,000 |
| End Cash Position | $40,597,000 | $31,239,000 |
| Beginning Cash Position | $31,239,000 | $23,332,000 |
| Changes In Cash | $9,358,000 | $7,907,000 |
| Net Issuance Payments Of Debt | $0 | $-171,000 |
| Net Long Term Debt Issuance | $0 | $-171,000 |
| Long Term Debt Payments | $0 | $-171,000 |
| Net Investment Purchase And Sale | $-71,142,000 | $-38,032,000 |
| Sale Of Investment | $150,750,000 | $8,000,000 |
| Purchase Of Investment | $-221,892,000 | $-46,032,000 |
| Net PPE Purchase And Sale | $-2,313,000 | $-1,772,000 |
| Purchase Of PPE | $-2,313,000 | $-1,772,000 |
| Change In Working Capital | $276,000 | $1,537,000 |
| Change In Other Current Liabilities | $-509,000 | $-538,000 |
| Change In Other Current Assets | $-98,000 | $0 |
| Change In Payables And Accrued Expense | $1,303,000 | $4,023,000 |
| Change In Accrued Expense | $1,123,000 | $2,305,000 |
| Change In Payable | $180,000 | $1,718,000 |
| Change In Account Payable | $180,000 | $1,718,000 |
| Change In Prepaid Assets | $-420,000 | $-1,948,000 |
| Other Non Cash Items | $48,000 | $528,000 |
| Stock Based Compensation | $2,388,000 | $1,388,000 |
| Unrealized Gain Loss On Investment Securities | $170,000 | $1,674,000 |
| Asset Impairment Charge | $393,000 | $0 |
| Amortization Of Securities | $-2,658,000 | $-681,000 |
| Depreciation Amortization Depletion | $804,000 | $313,000 |
| Depreciation And Amortization | $804,000 | $313,000 |
| Depreciation | $804,000 | $313,000 |
| Gain Loss On Sale Of PPE | $7,000 | $7,000 |
| Net Income From Continuing Operations | $-60,627,000 | $-39,801,000 |
Fetched: 2026-10-23